Current Health Canada instructions for use of the dopamine agonists (DA), pramipexole and ropinirole, state that Parkinson's disease (PD) patients should be told not to drive.
impaired alertness could put people at risk of serious injury or death e.g. operating machines. We are interested in your current practice, rather than what you believe is the correct answer or the legally appropriate thing to do."
The survey was distributed to 530 neurologists by the Canadian Neurological Society (CNS) via letter with directions to the website; 437 of these also received follow-up e-mails. In addition, the Canadian Movement Disorders Group (CMDG) sent an e-mail to 37 members (of whom six were not a member of the CNS). Responses were provided anonymously and to maintain anonymity, it was not recorded whether responders were a member of the CMDG. The survey was distributed between March and June 2006 and responses were collected up to August 2006.
RESULTS
In total 536 neurologists were contacted and 96 (17.9%) responded. Responses came from all provinces and most of the responders work in an urban population-dense area (Tables 1 and  2 ). Only 4.4% (95% confidence interval 0.3%-8.5%) advise patients with PD not to drive, solely because they are taking a DA (Table 3) . Respondents assess the patient's tendency for excessive daytime sleepiness and sleep attacks after starting a 
DISCUSSION
Although our study is limited by a low response rate, it is likely to be biased towards those respondents with a greater interest in PD and driving, indeed 27 out of 96 indicated a special interest in movement disorders. Reasons for the low response rate to our survey could be that the neurologists were wary of giving an opinion or had already made up their mind. It is also very likely that a proportion of the CNS members do not treat PD patients, which would affect the response rate. Another reason could be that, as the survey shows, clinicians do not perceive these side effects as a major problem. Only a small proportion of the clinicians responding to our survey advise patients not to drive, solely because they are taking a DA. This contrasts with the current Therapeutic Products Directorate Canada guidelines stating that PD patients using a DA "should be warned not to drive" based on reports of sudden onset of sleep ("sleep attacks") resulting in motor vehicle accidents. [1] [2] [3] [4] Driving restrictions have clear implications for patients' quality of life.
A number of factors intrinsic to PD might affect driving safety, including motor symptoms, mood disturbances, cognitive impairments, and visual deficits. 5 Nevertheless, general accident rates in PD are low. 6 Ritter and Steinberg 7 found PD patients to be involved in fewer accidents and traffic violation than the general population.
An important aspect of PD and driving safety is that dopaminergic drugs can cause drowsiness and rarely, sudden onset of sleep. 8, 9 The use of DA is associated with excessive daytime sleepiness. 10, 11 However, the frequency of excessive daytime sleepiness is nearly as high among patients who have never used a DA. 10 The use of dopaminergic drugs in early PD may even improve driving safety in a number of patients because it may improve movement, result in better sleep [12] [13] -thus improve alertness during the day -and it may improve cognition. [14] [15] [16] In accordance with the above, neurologists assess the patient's tendency for excessive daytime sleepiness and sleep attacks after starting a DA more frequently than after starting other dopaminergic drugs. However, neurologists' approach regarding excessive daytime sleepiness and driving safety in general is varied, including the frequency of assessments.
We advise regular assessment of patients regarding their sleepiness 11 and, if indicated, informing drivers to stop driving. 17 Drivers' awareness of their sleepiness while driving is not sufficient to prevent road traffic accidents. 17 Additionally, standardized visual and neuropsychological testing, including spatial perception, visuoconstructional abilities, nonverbal memory, and executive functioning, provide indices of key functional abilities in PD important for driving. 5 Overall, our study suggests that advising patients not to drive solely because they have PD and use a DA is too rigid in the opinion of most neurologists, who are caring for these patients. We propose that current Health Canada guidelines need revision in light of neurologists' current clinical practice.
